AMCP’s Post

Did you know that only about 36% of patients diagnosed with lung cancer receive the right treatment? Access the AMCP Market Insights report, Bridging the Gaps in Precision Oncology: Opportunities in Non-Small Cell Lung Cancer, to discover how effective referral, utilization management, and advanced diagnostics can improve patient outcomes and reduce costs. Visit the AMCP Market Insights resource page to learn more: https://bit.ly/4efCk4W #managedcare #pharmacy #oncology

Bispecific antibody therapy is emerging as a promising option for patients with advanced cancer. Lee Pendleton, PharmD, from Arizona Oncology in Prescott, helps patients and their families better understand how this innovative therapy works, its potential benefits, and what to expect. 📖arizonaoncology.com/blog #BispecificAntibodies #CancerTherapy #Oncology #AdvancedCancer #Pharmacology #PatientCare #Prescott #Arizona

It's not too late to register! Join us today at 1 & 8 PM ET for this live webinar on metastatic breast cancer! Learn more: https://bit.ly/3Kv18sa #PTCE #LiveWebinar #CEcredit #FreeCE #pharmacy #oncology #pharmacists #ContinuingEducation

New article in Drugs in Context Nivolumab plus ipilimumab with chemotherapy in metastatic NSCLC: minireview and a case study of a patient negative for PD-L1 Alessandro Morabito Clinical case of a patient who, despite testing negative for PD-L1, displayed a sustained complete response to immunotherapy treatment in advanced metastatic non-small-cell lung cancer along with a review of recent findings concerning the application of immunotherapy in this context. #drugsincontext #oncology #immunecheckpoints #nsclc #lungcancer #pdl1 #chemotherapy #pharmacology https://lnkd.in/eb2VmEJ6

Support your team with the insight they need to make decisions. Stay competitive with Oncology Resource Group's Pipeline Strategies Reports. Drug development for ovarian cancer has been shifting from IO and PARP inhibitors to ADCs. ONCrg stays on top of the news, big and small, to save your team time and to ensure competitor activities are reliably interpreted. Contact Brittany Daggett or Erica Wescott, MSc. to see more of our ONCrg Pipeline Strategies: Ovarian Cancer report, or for other solid tumors, hematologic malignancies, and MOAs. Unrivaled Insights, Unmatched Expertise #Oncology #CompetitiveStrategy #OvarianCancerAwareness #competitivelandscape

Such a huge win for ALK-positive NSCLC patients!! Patients will only benefit if we’re testing UPFRONT at first-line. Guardant CDx can provide that opportunity in less than 7 days. #alkpositive #nsclc #guardanthealth #concurrenttesting #liquidbiopsy #NCCNguidelines

ADCs: Transforming Oncology Drug Delivery Check out the latest article by Kenneth Barr, Ph.D. and Jayashree (Jay) Aiyar on the exciting potential of Antibody-Drug Conjugates (ADCs) in oncology. ADCs offer a compelling opportunity to deliver crucial, targeted cancer treatments, enhancing efficacy and reducing side effects. Dive into how these innovative therapies are shaping the future of oncology medications. To read the full article, visit 👉 https://lnkd.in/dHne2hxD #Oncology #ADCs #CancerTreatment #PharmaInnovation #TargetedTherapies

Abemaciclib, a targeted therapy for breast cancer, is emerging as the most dynamic molecule in the market. With its impressive efficacy, favorable side effect profile, and relatively simple regimen, it's paving the way for future treatments. This #BreastCancerAwarenessMonth, we acknowledge the significance of such advancements and reaffirm our commitment to providing the highest quality APIs for breast cancer management. Contact us for more details. API@polpharma.com CDMO@polpharma.com Product under Polpharma API - Egis Pharmaceuticals PLC cooperation #HPAPI #BreastCancerAwarenessMonth #oncology

🚨 🥁🥁🥁New FDA Approval 👉🏼Today the US FDA granted accelerated approval to tarlatamab-dlle (Imdelltra, Amgen, Inc.) for extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy @FDAOncology #SCLC 🎯 ⭐️Tarlatamab = bispecific T-cell engager (BiTE), a two-armed drug that simultaneously latches onto tumor cells and T cells, bringing them close together and helping the T cells recognize and destroy cancer cells https://lnkd.in/eTXAdS85

This must be the first approval in treatment refractory sclc for decades. It’s exciting to have a therapy against a novel target and in a disease that has such a poor prognosis overall. The duration of RR will be interesting to see in the RWE/ population